San Francisco, California – Immumem Therapeutics, an emerging biotechnology company focused on developing novel oncology therapeutics, today announced it has been awarded a $75,000 non-dilutive grant from ScaleReady’s G-Rex® Grant Program. This funding will support the advancement of Immumem’s innovative manufacturing processes for next-generation cell therapies.
The competitive grant provides Immumem with critical resources to expand its research platform and accelerate development timelines in the cell and gene therapy space. The award package includes access to advanced bioreactor technology, specialized reagents, and expert consulting services designed to enhance the company’s pre-clinical development capabilities.
“This non-dilutive funding represents a significant opportunity to accelerate our cell therapy manufacturing capabilities while preserving shareholder value,” stated a spokesperson for Immumem Therapeutics. “The support from ScaleReady’s G-Rex® Grant Program will enable us to optimize our production processes and advance our therapeutic pipeline toward key developmental milestones.”
The G-Rex® Grant Program is specifically designed to foster innovation within the cell and gene therapy sector by providing promising biotechnology companies with the resources needed to overcome manufacturing challenges and accelerate therapeutic development.
Immumem Therapeutics will utilize the grant to further refine its proprietary cell therapy manufacturing platform, with the goal of improving production efficiency and therapeutic potency. This advancement aligns with the company’s mission to develop more effective and accessible treatments for patients with cancer and other serious diseases.
For more information about Immumem Therapeutics and its development programs, please visit www.immumemtx.com or the company’s knowledge center.
About Immumem Therapeutics
Immumem Therapeutics is a biotechnology company headquartered in Richmond, California, dedicated to developing innovative therapies for oncology and other serious diseases with significant unmet medical needs. By leveraging cutting-edge cell engineering and manufacturing technologies, Immumem is working to create the next generation of effective therapeutic options for patients. Learn more at www.immumemtx.com.
Media Contact:
Corporate Communications
Immumem Therapeutics
media@immumemtx.com
(341) 799-5247
This press release contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in the forward-looking statements.